MX2009008701A - 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y su uso. - Google Patents
4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y su uso.Info
- Publication number
- MX2009008701A MX2009008701A MX2009008701A MX2009008701A MX2009008701A MX 2009008701 A MX2009008701 A MX 2009008701A MX 2009008701 A MX2009008701 A MX 2009008701A MX 2009008701 A MX2009008701 A MX 2009008701A MX 2009008701 A MX2009008701 A MX 2009008701A
- Authority
- MX
- Mexico
- Prior art keywords
- carbon black
- forming same
- black pellets
- pellet
- average thickness
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pigments, Carbon Blacks, Or Wood Stains (AREA)
Abstract
La presente solicitud se refiere a nuevas 4-aril-1,4-dihidro-1,6-n aftiridin-3-carboxamidas sustituidas, a procedimientos para su preparación, a su uso para el tratamiento y/o la profilaxis de enfermedades, así como a su uso para la preparación de fármacos para el tratamiento y/o la profilaxis de enfermedades, especialmente de enfermedades cardiovasculares.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102007009494A DE102007009494A1 (de) | 2007-02-27 | 2007-02-27 | Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung |
PCT/EP2008/001257 WO2008104306A2 (de) | 2007-02-27 | 2008-02-19 | Substituierte 4-aryl-1,4-dihydro-1,6-naphthyridinamide und ihre verwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009008701A true MX2009008701A (es) | 2009-08-27 |
Family
ID=39512753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009008701A MX2009008701A (es) | 2007-02-27 | 2008-02-19 | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y su uso. |
Country Status (45)
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2995317A1 (en) | 2010-05-26 | 2016-03-16 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
CN107375291A (zh) | 2011-10-28 | 2017-11-24 | 鲁美纳医药公司 | 用于治疗高胆血症和胆汁淤积性肝病的胆汁酸再循环抑制剂 |
MX354242B (es) | 2011-10-28 | 2018-02-20 | Lumena Pharmaceuticals Inc | Nhibidores de la recirculación de ácidos biliares para el tratamiento de enfermedades hepáticas colestásicas pediátricas. |
US10156567B2 (en) | 2012-12-17 | 2018-12-18 | General Electric Company | In-vitro magnetic resonance detection of a target substance without separating bound magnetic nanoparticles from unbound magnetic nanoparticles |
JP2016514678A (ja) | 2013-03-15 | 2016-05-23 | ルメナ ファーマシューティカルズ エルエルシー | バレット食道と胃食道逆流性疾患を処置するための胆汁酸再利用阻害剤 |
MX2015013193A (es) | 2013-03-15 | 2016-04-15 | Lumena Pharmaceuticals Inc | Inhibidores del reciclaje de acidos biliares para el tratamiento de colangitis esclerosante primaria y enfermedad inflamatoria intestinal. |
CN103193704B (zh) * | 2013-04-12 | 2016-03-09 | 四川铂瑞生物医药有限公司 | 2-羟基-4-氨基-5-甲基吡啶杂环化合物 |
EA029518B1 (ru) | 2014-06-30 | 2018-04-30 | Астразенека Аб | Бензоксазиноновые амиды в качестве модуляторов минералокортикоидного рецептора |
CN106795155B (zh) * | 2014-08-01 | 2023-06-16 | 拜耳医药股份有限公司 | 一种化合物的制备方法及其纯化以用作活性药物成分 |
WO2017006254A1 (en) | 2015-07-08 | 2017-01-12 | Novartis Ag | Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist |
EP3337799A1 (de) * | 2015-08-21 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Verfahren zur herstellung der metaboliten von (4s) und (4r)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxamid und deren verwendung |
ES2739904T3 (es) * | 2015-08-21 | 2020-02-04 | Bayer Pharma AG | Procedimiento para la preparación de (4S)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridina-3-carboxamida y su purificación para el uso como principio activo farmacéutico |
PE20180555A1 (es) * | 2015-08-21 | 2018-04-02 | Bayer Pharma AG | Procedimiento para la preparacion de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida y para la recuperacion de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida por medio de metodos electroquimicos |
US20180280414A1 (en) | 2015-10-13 | 2018-10-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation |
MX2018006474A (es) | 2015-12-02 | 2018-08-01 | Syngenta Participations Ag | Derivados de oxadiazol microbicidas. |
ES2973248T3 (es) | 2016-07-26 | 2024-06-19 | Inst Nat Sante Rech Med | Antagonista del receptor mineralocorticoide para el tratamiento de la osteoartritis |
EP3525779B1 (de) | 2016-10-11 | 2024-06-05 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend den sgc stimulator vericuguat und den mineralcorticoid-rezeptor-antagonist finerenone |
CN109890379A (zh) * | 2016-10-11 | 2019-06-14 | 拜耳制药股份公司 | 包含sGC活化剂和盐皮质激素受体拮抗剂的组合产品 |
WO2018153898A1 (de) * | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit mineralocorticoid-rezeptor-antagonisten |
WO2018219825A1 (en) | 2017-06-02 | 2018-12-06 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
DE102017008472A1 (de) | 2017-09-08 | 2018-05-03 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend PDE5 Inhibitoren und Mineralocorticoid-Rezeptor-Antagonisten |
CN109721536B (zh) * | 2017-10-27 | 2020-11-24 | 广东东阳光药业有限公司 | 苯基取代的稠合三环类化合物及其用途 |
EP3560922A1 (de) | 2018-04-24 | 2019-10-30 | Bayer Aktiengesellschaft | Verfahren zur herstellung von (4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carbox-amid durch racemat-spaltung mittels diastereomerer weinsäureester |
WO2019223629A1 (zh) * | 2018-05-22 | 2019-11-28 | 广东东阳光药业有限公司 | 苯基取代的二氢萘啶类化合物及其用途 |
CN110917195A (zh) * | 2018-08-20 | 2020-03-27 | 山西惠尔健生物科技有限公司 | 肌松剂阿库氯铵(Alcuronium chloride)可作为抗心律失常药物 |
JP2022519905A (ja) | 2019-02-12 | 2022-03-25 | ミルム ファーマシューティカルズ インコーポレイテッド | 胆汁酸塩排出ポンプ欠損症の患者における遺伝子型およびasbtiに対する用量依存的反応 |
PE20220251A1 (es) | 2019-03-05 | 2022-02-16 | Bayer Ag | Procedimiento para la preparacion de 4-amino-5-metilpiridona |
SG11202109546RA (en) | 2019-03-05 | 2021-09-29 | Bayer Ag | Synthesis of 4-amino-5-methyl-1h-pyridin-2(1h)-on (intermediate compound for the synthesis of the mr antagonist finerenone) from 2-chloro-5-methyl-4-nitro-pyridine-1-oxide using the intermediate compound 2-chloro-5-methyl-4-pyridinamine |
PE20221420A1 (es) * | 2019-10-17 | 2022-09-20 | Bayer Ag | Procedimiento fotoquimico para la preparacion de (4r,4s)-4-(4-ciano-2-metoxifenil)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-carboxamida |
JOP20220148A1 (ar) * | 2019-10-17 | 2023-01-30 | Bayer Ag | عملية لانتاج استرات أسيلوكسي مثيل من حمض (4s)- (4-سيانو-2-ميثوكسي فنيل)-5-ايثوكسي-2، 8-ثنائي مثيل-1، 4-ثنائي هيدرو-1، 6-نفثيريدين-3-كربوكسيليك |
CA3158165A1 (en) * | 2019-10-17 | 2021-04-22 | Bayer Aktiengesellschaft | Process for the preparation of (2-cyanoethyl (4s)-4-(4-cyano-2-methoxy-phenyl)-5-hydroxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxylate by racemate separation by means of diastereomeric tartaric acid esters |
CR20220157A (es) * | 2019-10-17 | 2022-06-02 | Bayer Ag | Procedimiento para preparar (4s)–4–(4–ciano–2–metoxi–fenil)–5–etoxi–2,8–dimetil–1,4–dihidro–1,6–naftiridin–3–carboxilato de 2–cianoetilo mediante separación de racematos utilizando ésteres diastereoméricos de ácido tartárico |
JP2023518168A (ja) | 2020-03-11 | 2023-04-28 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 対象が中心性漿液性脈絡網膜症を有するか、または有する危険性があるかどうかを決定する方法。 |
JP2023523596A (ja) | 2020-04-22 | 2023-06-06 | バイエル アクチェンゲゼルシャフト | 心血管疾患および/または腎疾患を治療および/または予防するためのフィネレノンとsglt2阻害剤の組み合わせ |
EP3900722A1 (en) | 2020-04-22 | 2021-10-27 | Bayer AG | Combination of finerenone and pecavaptan for the treatment and/or prevention of cardiovascular and/or renal diseases |
WO2021213493A1 (zh) * | 2020-04-24 | 2021-10-28 | 东莞市东阳光新药研发有限公司 | 二氢萘啶类化合物的晶型及其用途 |
CN113549066B (zh) * | 2020-04-24 | 2023-07-21 | 年衍药业(珠海)有限公司 | 二氢萘啶类化合物的晶型及其用途 |
WO2021254896A1 (en) | 2020-06-16 | 2021-12-23 | Bayer Aktiengesellschaft | Process for preparing (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide enabled by a catalytic asymmetric hantzsch ester reduction |
WO2022214206A1 (en) | 2021-04-08 | 2022-10-13 | Bayer Aktiengesellschaft | Combination of finerenone and pecavaptan for the treatment and/or prevention of cardiovascular and/or renal diseases |
WO2023004002A1 (en) * | 2021-07-21 | 2023-01-26 | Cyta Therapeutics, Inc. | Particle delivery of thyroid hormone receptor agonists and antagonists |
WO2023031277A1 (en) | 2021-08-31 | 2023-03-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of ocular rosacea |
TW202328127A (zh) * | 2021-09-18 | 2023-07-16 | 大陸商上海拓界生物醫藥科技有限公司 | 取代的1,4-二氫-1,6-萘啶醯胺及其用途 |
CN114149427A (zh) * | 2021-12-18 | 2022-03-08 | 上海鼎雅药物化学科技有限公司 | 非奈利酮及其中间体的合成方法 |
WO2023205164A1 (en) | 2022-04-18 | 2023-10-26 | Teva Pharmaceuticals International Gmbh | Processes for the preparation of finerenone |
EP4286368A1 (de) | 2022-05-31 | 2023-12-06 | Bayer Aktiengesellschaft | Verfahren zur herstellung von 4-formyl-3-methoxybenzonitril |
WO2024022481A1 (zh) * | 2022-07-29 | 2024-02-01 | 苏中药业集团股份有限公司 | 苯基取代的二氢萘啶类化合物及其制备与用途 |
WO2024110523A1 (en) | 2022-11-23 | 2024-05-30 | Bayer Aktiengesellschaft | Treatment of chronic kidney disease in type i diabetes mellitus |
WO2024126694A1 (en) | 2022-12-16 | 2024-06-20 | Bayer Aktiengesellschaft | Sequential one-pot synthesis for preparing 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide |
CN116715664A (zh) * | 2023-06-12 | 2023-09-08 | 常州制药厂有限公司 | 一种非奈利酮关键中间体的制备方法 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4698341A (en) * | 1983-07-30 | 1987-10-06 | Godecke Aktiengesellschaft | Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis |
DE3327650A1 (de) | 1983-07-30 | 1985-02-14 | Gödecke AG, 1000 Berlin | 1,6-naphthyridinon-derivate, verfahren zu deren herstellung und deren verwendung bei der bekaempfung von gefaesserkrankungen |
DE3502831A1 (de) | 1985-01-29 | 1986-07-31 | Gödecke AG, 1000 Berlin | 1,6-naphthyridinon-derivate, verfahren zu deren herstellung und deren verwendung |
IL75987A (en) | 1984-08-25 | 1991-07-18 | Goedecke Ag | Tri-and tetrasubstituted-1,4-dihydro-1,6-naphthyridine-3-carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them |
US4760081A (en) * | 1984-08-25 | 1988-07-26 | Goedecke Aktiengesellschaft | 1,6-naphthyridine derivatives useful for treating diseases of the blood vessels |
DE3431303A1 (de) | 1984-08-25 | 1986-02-27 | Goedecke Ag | 1,6-naphthyridin-derivate, verfahren zu deren herstellung und deren verwendung |
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
JP2004505081A (ja) | 2000-08-02 | 2004-02-19 | アボット・ラボラトリーズ | ジヒドロナフチリジンカリウムチャンネルオープナー |
AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
US7563748B2 (en) | 2003-06-23 | 2009-07-21 | Cognis Ip Management Gmbh | Alcohol alkoxylate carriers for pesticide active ingredients |
DE102004012365A1 (de) | 2004-03-13 | 2005-09-29 | Bayer Healthcare Ag | Substituierte Dihydropyridine |
JP2007230869A (ja) | 2004-04-05 | 2007-09-13 | Takeda Chem Ind Ltd | アルドステロン受容体拮抗剤 |
RU2346996C2 (ru) | 2004-06-29 | 2009-02-20 | ЮРОПИЭН НИКЕЛЬ ПиЭлСи | Усовершенствованное выщелачивание основных металлов |
WO2006066011A2 (en) | 2004-12-13 | 2006-06-22 | Irm Llc | Compounds and compositions as modulators of steroidal receptors and calcium channel activities |
DE602006020138D1 (de) | 2005-06-29 | 2011-03-31 | Compumedics Ltd | Sensoranordnung mit leitfähiger brücke |
DE102005034264A1 (de) | 2005-07-22 | 2007-02-01 | Bayer Healthcare Ag | 4-Chromenonyl-1,4-dihydropyridincarbonitrile und ihre Verwendung |
DE102006026583A1 (de) * | 2006-06-07 | 2007-12-13 | Bayer Healthcare Aktiengesellschaft | Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung |
DE102006026585A1 (de) * | 2006-06-07 | 2007-12-13 | Bayer Healthcare Aktiengesellschaft | Substituierte 4-Aryl-1,4-dihydro-1,6-naphthyridine und ihre Verwendung |
-
2007
- 2007-02-27 DE DE102007009494A patent/DE102007009494A1/de not_active Withdrawn
-
2008
- 2008-02-17 SA SA8290071A patent/SA08290071B1/ar unknown
- 2008-02-18 PA PA20088770101A patent/PA8770101A1/es unknown
- 2008-02-19 MY MYPI20093470 patent/MY150748A/en unknown
- 2008-02-19 PT PT87158499T patent/PT2132206E/pt unknown
- 2008-02-19 CL CL200800502A patent/CL2008000502A1/es unknown
- 2008-02-19 SI SI200831451T patent/SI2132206T1/sl unknown
- 2008-02-19 WO PCT/EP2008/001257 patent/WO2008104306A2/de active Application Filing
- 2008-02-19 NZ NZ579230A patent/NZ579230A/en unknown
- 2008-02-19 UA UAA200909818A patent/UA102065C2/ru unknown
- 2008-02-19 DK DK08715849.9T patent/DK2132206T3/en active
- 2008-02-19 CA CA2679232A patent/CA2679232C/en active Active
- 2008-02-19 PL PL08715849T patent/PL2132206T3/pl unknown
- 2008-02-19 HU HUE08715849A patent/HUE026441T2/en unknown
- 2008-02-19 BR BRPI0808098A patent/BRPI0808098B8/pt active IP Right Grant
- 2008-02-19 JP JP2009550238A patent/JP5367586B2/ja active Active
- 2008-02-19 MY MYPI2013000708A patent/MY176873A/en unknown
- 2008-02-19 UY UY30931A patent/UY30931A1/es active IP Right Grant
- 2008-02-19 BR BR122020008544A patent/BR122020008544B8/pt active IP Right Grant
- 2008-02-19 UY UY0001038953A patent/UY38953A/es not_active Application Discontinuation
- 2008-02-19 UY UY0001038952A patent/UY38952A/es not_active Application Discontinuation
- 2008-02-19 EP EP08715849.9A patent/EP2132206B1/de active Active
- 2008-02-19 ES ES08715849.9T patent/ES2540803T3/es active Active
- 2008-02-19 PE PE2008000351A patent/PE20090724A1/es active IP Right Grant
- 2008-02-19 AU AU2008221071A patent/AU2008221071B2/en active Active
- 2008-02-19 US US12/526,951 patent/US8436180B2/en active Active
- 2008-02-19 MX MX2009008701A patent/MX2009008701A/es active IP Right Grant
- 2008-02-19 CN CN2008800063770A patent/CN101641352B/zh active Active
- 2008-02-19 KR KR1020097017818A patent/KR101614164B1/ko active IP Right Grant
- 2008-02-25 AR ARP080100769A patent/AR065463A1/es active IP Right Grant
- 2008-02-26 TW TW097106529A patent/TWI415608B/zh active
- 2008-02-26 TW TW102122083A patent/TWI474821B/zh active
- 2008-02-26 JO JOP/2008/0080A patent/JO3018B1/ar active
-
2009
- 2009-07-23 IL IL200060A patent/IL200060A/en active IP Right Grant
- 2009-07-30 TN TNP2009000318A patent/TN2009000318A1/fr unknown
- 2009-08-13 GT GT200900230A patent/GT200900230A/es unknown
- 2009-08-14 DO DO2009000205A patent/DOP2009000205A/es unknown
- 2009-08-14 CU CUP2009000148A patent/CU23874B1/es active IP Right Grant
- 2009-08-14 CR CR10976A patent/CR10976A/es unknown
- 2009-08-14 HN HN2009001597A patent/HN2009001597A/es unknown
- 2009-08-14 EC EC2009009581A patent/ECSP099581A/es unknown
- 2009-08-18 CO CO09085903A patent/CO6220951A2/es not_active Application Discontinuation
- 2009-08-18 ZA ZA200905730A patent/ZA200905730B/xx unknown
- 2009-09-10 MA MA32211A patent/MA31245B1/fr unknown
-
2010
- 2010-06-28 HK HK10106307.3A patent/HK1140194A1/xx unknown
-
2013
- 2013-03-13 US US13/801,376 patent/US9051316B2/en active Active
- 2013-08-05 JP JP2013162179A patent/JP5752754B2/ja active Active
-
2015
- 2015-06-30 HR HRP20150702TT patent/HRP20150702T1/hr unknown
- 2015-06-30 CY CY20151100566T patent/CY1116455T1/el unknown
-
2022
- 2022-05-03 HU HUS2200015C patent/HUS2200015I1/hu unknown
- 2022-05-05 FR FR22C1017C patent/FR22C1017I2/fr active Active
- 2022-06-21 LT LTPA2022512C patent/LTPA2022512I1/lt unknown
- 2022-08-11 NL NL301192C patent/NL301192I2/nl unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009008701A (es) | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y su uso. | |
MX337136B (es) | Particula de suministro. | |
EP2280400A4 (en) | PROCESS FOR PRODUCTION OF NUCLEAR FUEL PASTIL, FUEL ASSEMBLY, PROCESS FOR PRODUCTION OF FUEL ASSEMBLY, AND URANIUM POWDER | |
EP2289360A3 (en) | Molded motorcycle helmet and method of manufacture | |
GB2478209A (en) | Polymer thermal interface materials | |
MX2011011006A (es) | Complemento alimenticio granular. | |
EP1961701A4 (en) | GRAPHITE PARTICLE, CARBON-GRAPHITE COMPOSITE PARTICLE, AND PROCESSES FOR PRODUCING THE SAME | |
EP2154694A4 (en) | SOFT MAGNETIC MATERIAL, MAGNETIC POWDER CORE, METHOD FOR PRODUCING SOFT MAGNETIC MATERIAL AND METHOD FOR PRODUCING THE MAGNETIC POWDER CORE | |
EP2166119A4 (en) | SCHUPPENGRAPHIT CAST IRON AND MANUFACTURING METHOD THEREFOR | |
MY162975A (en) | Fabrication of core/shell capsules of different geometries and treatment thereafter | |
WO2008138004A3 (en) | Solid fuel compositions, processes for preparing solid fuel, and combustion processes | |
AP2011005995A0 (en) | Method for the production of commercial nanoparticle and microparticle powders. | |
WO2011139582A3 (en) | Exhaust-gas turbocharger | |
EP2022995A4 (en) | NEEDLE BEARING WITH SEAL AND ITS MANUFACTURING METHOD | |
GB201012797D0 (en) | Hydrogen generator and fuel pellet | |
WO2009030703A3 (en) | Novel nanoparticles | |
ZA200901394B (en) | Dual stage process for the rapid formation of pellets | |
WO2008007290A3 (en) | Core-shell nanoparticles for thearapy and imaging purposes | |
EP2143559A4 (en) | MAGNESIUM ALLOY COMPOSITE MATERIAL AND METHOD FOR MANUFACTURING THE SAME | |
EP2275582A4 (en) | MEASURING ALLOY POWDER, EXTRUDED MEASUREMENT ALLOY MATERIAL, AND METHOD FOR PRODUCING THE EXTRUDED MEASUREMENT ALLOY MATERIAL | |
ZA201001331B (en) | Process for producing reduced iron pellets, and process for producing pig iron | |
TN2010000163A1 (en) | Lipoic acid pellet composition | |
EP2211405A4 (en) | POWDERED NICKEL OXIDE MATERIAL FOR SOLID OXIDE FUEL CELLS, PROCESS FOR PRODUCING POWDERED NICKEL OXIDE MATERIAL AND FUEL ELECTRODE MATERIAL, FUEL ELECTRODE, AND SOLID OXIDE FUEL CELL USING THE POWDER MATERIAL NICKEL OXIDE | |
PL2122067T3 (pl) | Zintegrowane siatki z poli(tereftalanu etylenu), sposób ich wytwarzania i zastosowania | |
WO2012007660A9 (fr) | Electrode de reference miniature |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH |
|
FG | Grant or registration |